WuXi Biologics has unveiled its WuXia ADCC PLUS platform to develop and produce afucosylated antibodies that elicit enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) effect.

WuXia ADCC PLUS is a superior-performing and high-yielding mammalian cell line platform. It is derived from the company’s WuXia cell line platform.

The platform is designed to produce afucosylated antibodies that can increase ADCC, offering diverse bioprocessing solutions for international clients.

WuXi Biologics, a contract research, development, and manufacturing organisation (CRDMO), said the cell line platform is intended to address the market requirement for better antibody therapeutic efficacy.

In addition, the WuXiaADCC PLUS cell line is said to be compatible with the WuXia platform process. This allows a stable production of the afucosylated antibodies at various scales for clinical and commercial production.

WuXi Biologics CEO Chris Chen said: “We are pleased to launch WuXiaADCC PLUSTM to provide a new bioprocessing solution for our global clients developing novel antibody therapies.

“WuXi Biologics’ continual launch of new technology platforms comes from our drive to push boundaries and foster innovation – all with the goal of enabling our global partners to bring more high-quality and affordable biologics to patients worldwide.”

According to the Chinese CRDMO, ADCC is a key mechanism behind targeted antibody-based immunotherapy techniques.

The development of new cancer therapeutics involves creating and developing antibodies with a greater capacity to increase the ADCC response.

This process is known to enhance therapeutic efficacy and patient outcomes, WuXi Biologics said.

The company offers end-to-end solutions, from concept to commercialisation to enable partners to discover, develop and manufacture biologics.

WuXi is assisting 698 integrated customer projects as of 31 December 2023, 24 of which are in commercial manufacturing.

Recently, the Chinese firm forged a research service agreement with German biotechnology company BioNTech to develop new therapeutic candidates.

Under the deal, WuXi will use its antibody discovery technology platforms to discover two preclinical investigational monoclonal antibodies for BioNTech.